Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,346 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo, intravenous Clear all
Terminated Phase 3 Interventional Results available

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

NCT02620384
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Experimental: Placebo, Experimental: Metolazone
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Early Phase 1 Interventional

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

NCT03763643
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Rituximab, Plasmapheresis
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
1 Year to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

NCT01794663
View directory record Official record
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 27, 2026, 5:41 PM EDT
Not listed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

NCT04780685
View directory record Official record
Conditions
Covid19
Interventions
hMSC
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Fullerton, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Red Blood Cell ATP Release and Vascular Function in Humans

NCT03404843
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Fasudil Hydrochloride, Saline
Drug · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

NCT05238493
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VEL-101, Placebo
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 4 Interventional

Trial of Parkinson's And Zoledronic Acid

NCT03924414
View directory record Official record
Conditions
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Interventions
Zoledronic Acid 5Mg/Bag 100Ml Inj, Placebo
Drug · Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
60 Years and older
Enrollment
2,721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
77
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

NCT04537806
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Brexanolone, Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain

NCT05010148
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Pain, Spinal Fusion
Interventions
Lidocaine IV, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Nitrous Oxide for PTSD

NCT04378426
View directory record Official record
Conditions
PTSD
Interventions
Nitrous Oxide, Midazolam, Nitrogen, Oxygen, Saline
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

US Phase III Study of APD421 in PONV

NCT01991860
View directory record Official record
Conditions
PONV
Interventions
APD421- Amisulpride for IV injection, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

NCT02221947
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04990440
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Bermekimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

NCT00184548
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 27, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, placebo, methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 27, 2026, 5:41 PM EDT
Withdrawn Phase 2 Interventional

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure

NCT05633758
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Placebo, Metolazone
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 27, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
View directory record Official record
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 27, 2026, 5:41 PM EDT
Not listed Phase 1 Interventional

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

NCT00265278
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Modafinil
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 27, 2026, 5:41 PM EDT